Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Novo Nordisk to Build $400 Million China Manufacturing Plant

publication date: Nov 10, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Novo Nordisk will invest almost $400 million to build a very large insulin manufacturing facility in Tianjin. The new facility will function as the company’s primary production site in China and serve the entire Asia Pacific region. The new 22,500 sq. meter plant, which will employ almost 500 people, is expected to become operational in 2012. The facility will be built on a site adjacent to Novo Nordisk’s existing manufacturing plant in Tianjin. More details...

Stock Symbol: (NYSE: NVO)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...